Author's response to reviews

Title: Membranoproliferative glomerulonephritis with predominant IgG2 and IgG3 deposition in a patient with IgG4-related disease

Authors:

Kenji Ueki (ken810@tkz.bbiq.jp)
Yuta Matsukuma (ym09045180792@yahoo.co.jp)
Kosuke Masutani (masutani@kcu.med.kyushu-u.ac.jp)
Akihiro Tsuchimoto (tucimoto@intmed2.med.kyushu-u.ac.jp)
Kiichiro Fujisaki (kiichiro.fujisaki@nifty.ne.jp)
Kumiko Torisu (torisuk@kcu.med.kyushu-u.ac.jp)
Tamotsu Kiyoshima (kiyo@dent.kyushu-u.ac.jp)
Satoshi Hisano (hisanos1@cis.fukuoka-u.ac.jp)
Takanari Kitazono (kitazono@intmed2.med.kyushu-u.ac.jp)
Kazuhiko Tsuruya (tsuruya@intmed2.med.kyushu-u.ac.jp)

Version: 2
Date: 26 May 2015

Author's response to reviews: see over
May 26, 2015

Hayley Henderson
Executive Editor
*BMC Nephrology*

Dear Dr. Henderson

Please find the uploaded manuscript entitled “Membranoproliferative glomerulonephritis with predominant IgG2 and IgG3 deposition in a patient with IgG4-related disease” by Ueki K *et al.*, for consideration for publication in *BMC Nephrology*.

This is the first report of a case of IgG4-related kidney disease (RKD) and membranoproliferative glomerulonephritis showing the discrepancy in IgG subclasses between the kidney interstitium and glomeruli. Different patterns of IgG subclasses detected in the glomeruli and interstitial plasma cells suggest overlapping immunologic abnormalities. IgG4-RD is a novel disease entity and the detailed pathophysiology is still unknown; thus, this emphasizes the need to accumulate the details of more cases of IgG4-RKD, and perform IgG subclass staining extensively if glomerular lesions are found in IgG4-RKD to clarify the nature of this disease.

We confirm that (1) the manuscript has been approved by all authors, (2) no financial support or benefits have been received by any authors, and (3) the material included in this paper has not been published so far and this manuscript is not under consideration for publication elsewhere.

I hope that the reviewing process finds the manuscript acceptable for publication in *BMC Nephrology*.

Sincerely,

Kazuhiko Tsuruya, M.D., Ph.D.
Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University
3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
Tel: +81-92-642-5843
Fax: +81-92-642-5846
E-mail: tsuruya@intmed2.med.kyushu-u.ac.jp

**Point-by-point description of the changes made**

**Editorial Request:**

1. **Consent**

   Please confirm that the patient has given their consent for the case report to be published and please include a Consent section in the manuscript stating that consent has been obtained. The editorial office may request copies of the informed consent documentation at any time. We recommend the following wording is used for the consent section: “Written informed consent was obtained from the patient for publication of this case report and any
accompanying images. A copy of the written consent is available for review by the Editor of this journal.

**Response to comment 1**
We have uploaded a pdf file of the written informed consent obtained from the patient for publication of this case report and any accompanying images.

**2. Competing Interest**
Please include a 'Competing interests' section between the Conclusions and Authors' contributions. If there are none to declare, please write 'The authors declare that they have no competing interests'. Please consider the following questions and include a declaration of competing interests in your manuscript:

**Financial competing interests**
- In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
- Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
- Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
- Do you have any other financial competing interests? If so, please specify.

**Non-financial competing interests**
- Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.

**Response to comment 2**
We have included a Competing interests section between the Conclusions and Acknowledgements.

**3. Authors Contribution**
Please include an Authors' contributions section before the Acknowledgements and Reference list. For the Authors' contributions we suggest the following kind of format (please use initials to refer to each author's contribution): AB carried out the molecular genetic studies, participated in the sequence alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in the sequence alignment. ES participated in the design of the study and performed the statistical analysis. FG conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript. An “author” is generally considered to be someone who has made substantive intellectual contributions to a published study. To qualify as an author one should 1) have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) have been involved in drafting the manuscript or revising it critically for important intellectual content; and 3) have given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Acquisition of funding, collection of
data, or general supervision of the research group, alone, does not justify authorship.
All contributors who do not meet the criteria for authorship should be listed in an
acknowledgements section. Examples of those who might be acknowledged include a person
who provided purely technical help, writing assistance, or a department chair who provided
only general support.

**Response to comment 3**
We have included an Authors' contributions section before the Acknowledgements and
Reference list.

**4. Care Checklist**
BMC Nephrology endorses the CARE Guidelines
(http://www.jmedicalcasereports.com/series/CAREguidelines). Case reports submitted to the
journal must have a populated CARE checklist included as an additional file. A Word file of
the checklist and flow diagram can be downloaded here:

**Response to comment 4**
We have checked the manuscript according to the CARE checklist and uploaded it.

**5. Abbreviation**
Please Add if any

**Response to comment 5**
We have included a List of abbreviations.